Media
TAMP-Mediated Gemcitabine Lowers Systemic Exposure vs IV Delivery in Locally Advanced Pancreatic Cancer
September 2, 2026
A pharmacokinetic sub-study of the phase 3 TIGeR-PaC trial shows TAMP-delivered gemcitabine significantly lowers systemic exposure compared to standard IV…
The Most Innovative Medical Device Companies of 2026
May 8, 2026
Why RenovoRx, Medtronic, Uresta, and Cionic are among the 10 most innovative companies making medical devices right now.…
Mark Voll Joins RenovoRx as Chief Financial Officer
February 19, 2026
RenovoRx Inc. has welcomed a new member to its senior leadership team, hiring Mark Voll as chief financial officer (CFO),…
Why Commercial Discipline Starts Long Before Launch
February 17, 2026
Shaun Bagai is the CEO of RenovoRx, a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a…
Interview with Shaun Bagai: Revolutionary Cancer Treatment, Startup Success, & Medtech Mentorship
January 23, 2026
Shaun Bagai is the CEO and Director of RenovoRx, and a seasoned MedTech leader whose path began with a Silicon…
Nanoparticles and Beyond: Novel Drug Delivery Strategies for Cancer
January 13, 2026
A major breakthrough in cancer drug delivery took place in 1995, when the FDA approved the first nanodrug, Doxil—a liposomal…
Revolutionizing Cancer Treatment: The Future of Localized Drug Delivery to Tumors with CEO Shaun Bagai
November 25, 2025
In this compelling episode of MedTech 101, host Rodney Moses sits down with RenovoRx CEO Shaun Bagai to explore the…
First Patient Treated in RenovoCath Clinical Trial
November 10, 2025
RenovoRx Inc.’s study of its U.S. Food and Drug Administration (FDA)-cleared drug delivery device, RenovoCath, has marked a major milestone…
Expanding Solid Tumor Care: Shaun Bagai from RenovoRx in a Stimulating Conversation with PharmaShots
September 29, 2025
Shaun Bagai, CEO of RenovoRx, shares insights on the company’s recent patents, ongoing clinical trials, and its upcoming presentation at…